VON WILLEBRAND DISEASE (VWD)

This study tests a new medicine, HMB-002, in 108 adults with von Willebrand disease (types 1 and 2). The goal is to check if the drug is safe, how the body processes it, and whether it helps control bleeding. Participants will receive either one or several doses of the drug, and …

This study tests a new medicine called VGA039, given as a shot under the skin, to prevent bleeding episodes in people with Von Willebrand disease (VWD). The trial includes 60 adolescents and adults aged 12 to 75 who have frequent bleeding (12 or more bleeds per year). The goal is…

This study tests whether a step-by-step care plan (algorithm) can lower the chance of another serious bleed in people with von Willebrand disease. It compares the new plan to standard care in 66 adults who have had a gastrointestinal bleed or severe nosebleed. The goal is to see …

This study tests whether a monthly infusion of vonicog alfa (a lab-made clotting protein) can prevent bleeding episodes in 24 children with severe von Willebrand disease. Participants receive the treatment for 12 months and have 5 clinic visits. The main goal is to see if the ann…

This program offers continued access to an unlicensed medicine called recombinant von Willebrand factor (rVWF) for children and adults with severe von Willebrand disease who have already benefited from it in a previous study. Participants must have completed at least 12 months of…

This study tests whether a drug called VONVENDI is safe and helps control bleeding in 20 Chinese adults with von Willebrand disease, a condition that makes blood clot poorly. Some participants may also receive ADVATE if needed. The study lasts about 14 months and includes clinic …

This study looks at how safe and effective the drug Vonvendi (rVWF) is for children under 18 with von Willebrand disease, a bleeding disorder. Researchers will track side effects and how well the drug controls bleeding over one year. The study is being done in Japan as part of ro…

This study looks at special cells from blood vessels (called ECFCs) in people with von Willebrand disease, acquired von Willebrand syndrome, and healthy volunteers. Researchers want to see how these cells make and release a key clotting protein. The goal is to better understand t…

This study is gathering information about bleeding episodes, quality of life, and treatment use in 200 people with von Willebrand disease (VWD). Participants will report their bleeding events and complete surveys over time. The data will help researchers understand the daily impa…